NCT06531811View on ClinicalTrials.gov

A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants.

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

October 3, 2024

Study Completion Date

October 3, 2024

Conditions
Healthy Participants
Interventions
DRUG

AZD8630 (test formulation) via test inhaler

Participants will receive AZD8630 via test inhaler.

DRUG

AZD8630 (reference formulation) via Monodose inhaler

Participants will receive AZD8630 via Monodose inhaler.

DEVICE

Test inhaler

Participants will receive AZD8630 via test inhaler.

DEVICE

Monodose inhaler

Participants will receive AZD8630 via Monodose inhaler.

Trial Locations (1)

21225

Research Site, Baltimore

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY